AR070527A1 - Bloqueadores poliaromaticos del canal de sodio - Google Patents
Bloqueadores poliaromaticos del canal de sodioInfo
- Publication number
- AR070527A1 AR070527A1 ARP090100664A ARP090100664A AR070527A1 AR 070527 A1 AR070527 A1 AR 070527A1 AR P090100664 A ARP090100664 A AR P090100664A AR P090100664 A ARP090100664 A AR P090100664A AR 070527 A1 AR070527 A1 AR 070527A1
- Authority
- AR
- Argentina
- Prior art keywords
- chor8
- het
- nr13r13
- conr13r13
- ch2ch2o
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
- C07D241/32—(Amino-pyrazinoyl) guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Se proporcionan bloqueadores del canal de sodio poliaromáticos, así como también una variedad de composiciones, combinaciones y métodos de tratamiento que emplean estos bloqueadores del canal de sodio de la presente. Reivindicacion 1: Un compuesto representado por la formula (1) y racematos, enantiomeros, diastereomeros, tautomeros, polimorfos, pseudopolimorfos y sales farmacéuticamente aceptables de dicho compuesto, en donde X es hidrogeno, halogeno, trifluorometilo, alquilo inferior, fenilo sustituido o no sustituido, alquilo inferior-tio, fenil-alquilo inferior-tio, alquilo inferior-sulfonilo o fenil-alquilo inferior-sulfonilo; Y es hidrogeno, hidroxilo, mercapto, alcoxi inferior, alquilo inferior-tio, halogeno, alquilo inferior, arilo mononuclear sustituido o no sustituido, o -N(R2)2; R1 es hidrogeno o alquilo inferior; cada R2 es, independientemente, -R7, -(CH2)m-OR8, (CH2)m-NR7R10, -(CH2)n(CHOR8)(CHOR8)n-CH2OR8, -(CH2CH2O)m-R8, (CH2CH2O)m-CH2CH2NR7R10, -(CH2)n-C(=O)NR7R10, -(CH2)n-(Z)g-R7, (CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-CO2R7, o un resto de formula (2a); R3 y R4 son cada uno, independientemente, hidrogeno, alquilo inferior, hidroxil-alquilo inferior, fenilo, (fenil)-alquilo inferior, (halofenil)-alquilo inferior, ((alquilo inferior)fenil)-alquilo inferior, ((alcoxi inferior)fenil)-alquilo inferior, (naftil)-alquilo inferior o (piridil)-alquilo inferior, o un grupo representado por la formula A o formula B, con la condicion de que al menos uno de R3 y R4 sea un grupo representado por la formula A o formula B; formula A: -(C(RL)2)o-x-(C(RL)2)pA1 formula B: -(C(RL)2)o-x-(C(RL)2)pA2 A1 es un carbociclo aromático de C7-15 miembros sustituido con al menos un R5, y los sustituyentes restantes son R6; A2 es un heterociclo aromático de siete a quince miembros sustituido con al menos un R5, y los sustituyentes restantes son R6, en donde dicho heterociclo aromático comprende 1-4 heteroátomos seleccionados del grupo que consiste en O, N y S; cada RL es, independientemente, -R7, -(CH2)n-OR8, O-(CH2)m-OR8, -(CH2)n-NR7R10, -O-(CH2)m-NR7R10, -(CH2)n(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m(CHOR8)(CHOR8)n-CH2OR8, -(CH2CH2O)m-R8, -O-(CH2CH2O)m-R8, -(CH2CH2O)m-CH2CH2NR7R10, -O-(CH2CH2O)m-CH2CH2NR7R10, -(CH2)n-C(=O)NR7R10, -O-(CH2)m-C(=O)NR7R10, -(CH2)n-(Z)g-R7, O-(CH2)m-(Z)g-R7, -(CH2)n-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-CO2R7, -O-(CH2)m-CO2R7, OSO3H, -O-glucuronida, -O-glucosa, o los restos de formulas (2) y (3); cada o es, independientemente, un numero entero de 0 a 10; cada p es, independientemente, un numero entero de 0 a 10; con la condicion de que la suma de o y p en cada cadena contigua sea de 1 a 10; cada x es, independientemente, O, NR10, C(=O), CHOH, C(=N-R10), CHNR7R10 o un enlace simple; cada R5 es, independientemente, OH, -(CH2)m-OR8, -O-(CH2)m-OR8, -(CH2)n-NR7R10, -O-(CH2)m-NR7R10, -(CH2)n-(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m-(CHOR8)(CHOR8)n-CH2OR8, -(CH2CH2O)m-R8, -O-(CH2CH2O)m-R8, -(CH2CH2O)m-CH2CH2NR7R10, -O-(CH2CH2O)m-CH2CH2NR7R10, -(CH2)n-C(=O)NR7R10, -O-(CH2)m-C(=O)NR7R10, -(CH2)n-(Z)g-R7, -O-0(CH2)m-(Z)g-R7, -(CH2)n-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-CO2R7, -O-(CH2)m-CO2R7, -OSO3H, -O-glucuronida, -O-glucosa, los restos de formulas (2), (3) y (4), -(CH2)n-CO2R13, -Het-(CH2)m-CO2R13, -(CH2)n-(Z)g-CO2R13, -Het-(CH2)m-(Z)g-CO2R13, -(CH2)n-NR10-(CH2)m(CHOR8)n-CO2R13, -Het-(CH2)m-NR10-(CH2)m-(CHOR8)n-CO2R13, -(CH2)n-(CHOR8)m-CO2R13, -Het-(CH2)m-(CHOR8)m-CO2R13, -(CH2)n-(CHOR8)m(Z)g-CO2R13, -Het-(CH2)n-(CHOR8)m-(Z)g-CO2R13, -(CH2)n-(Z)g-(CH2)m-CO2R13, -(CH2)n-(Z)g(CHOR8)m-(Z)g-CO2R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-CO2R13, -(CH2)n-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-CO-NH-C(=NR13)-NR13R13, -(CH2)n-(Z)g-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-(Z)g-CONH-C(=NR13)-NR13R13, -(CH2)n-NR10-(CH2)m(CHOR8)n-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-NR10-(CH2)m(CHOR8)n-CONH-C(=NR13)-NR13R13, -(CH2)n-(CHOR8)m-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-(CHOR8)mCONH-C(=NR13)-NR13R13, -(CH2)n-(CHOR8)m-(Z)g-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-CONH-C(=NR13)-NR13R13, -(CH2)n-(Z)g-(CH2)m-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-(Z)g-(CH2)m-CONH-C(=NR13)-NR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONH-C(=NR13)-NR13R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONH-C(=NR13)-NR13R13, -(CH2)n-CONR7-CONR13R13, -Het-(CH2)n-CONR7-CONR13R13, -(CH2)n-(Z)g-CONR7-CONR13R13, -(CH2)n-NR10-(CH2)m(CHOR8)m-CONR7-CONR13R13, -Het-(CH2)n-NR10, -(CH2)m(CHOR8)n-CONR7-CONR13R13, -(CH2)n-(CHOR8)m-CONR7-CONR13R13, Het-(CH2)n-(CHOR8)m-CONR7-CONR13R13, -(CH2)n-(CHOR8)m-(Z)g-CONR7-CONR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-CNR7-CONR13R13, -(CH2)n-(Z)g-(CH2)m-CONR7-CONR13R13, -Het-(CH2)n-(Z)g-(CH2)m-CONR7-CONR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR7-CONR13R13, -Het-(CH2)n-(Z)g(CHOR8)m-(Z)g-CONR7-CONR13R13, -(CH2)n-CONR7SO2NR13R13, -Het-(CH2)m-(Z)g-CONR7SO2NR13R13, -(CH2)n-(Z)g-CONR7SO2NR13R13, -Het-(CH2)m-(Z)g-CONR7SO2NR13R13, -(CH2)n-NR10-(CH2)m(CHOR8)n-CONR7SO2NR13R13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-CONR7SO2NR13R13, -(CH2)n-(CHOR8)m-CONR7SO2NR13R13, -Het-(CH2)m-(CHOR8)m-CONR7SO2NR13R13, -(CH2)n-(CHOR8)m-(Z)g-CONR7SO2NR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-CONR7SO2NR13R13, -(CH2)n-(Z)g-(CH2)m-CONR7SO2NR13R13, -Het-(CH2)n-(Z)g-(CH2)m-CONR7SO2NR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR7SO2NR13R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR7SO2NR13R13, -(CH2)n-SO2NR13R13, -Het-(CH2)m-SO2NR13R13, -(CH2)-(Z)g-SO2NR13R13, -Het-(CH2)m-(Z)g-SO2NR13R13, -(CH2)n-NR10-(CH2)m(CHOR8)n-SO2NR13R13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-SO2NR13R13, -(CH2)n-(CHOR8)m-SO2NR13R13, -Het-(CH2)m-(CHOR8)m-SO2NR13R13, -(CH2)n-(CHOR8)m-(Z)g-SO2NR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-SO2NR13R13, -(CH2)n-(Z)g-(CH2)m-SO2NR13R13, -Het-(CH2)n-(Z)g-(CH2)m-SO2NR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-SO2NR13R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-SO2NR13R13, -(CH2)n-CONR13R13, -Het-(CH2)m-CONR13R13, -(CH2)n-(Z)g-CONR13R13, -Het-(CH2)m-(Z)g-CONR13R13, -(CH2)n-NR10-(CH2)m(CHOR8)n-CONR13R13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-CONR13R13, -(CH2)n-(CHOR8)m-CONR13R13, -Het-(CH2)n-(CHOR8)m-CONR13R13, -(CH2)n-(CHOR8)m-(Z)g-CONR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-CONR13R13, -(CH2)n-(Z)g-(CH2)m-CONR13R13, -Het-(CH2)n-(Z)g-CONR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR13R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR13R13, -(CH2)n-CONR7COR13, -Het-(CH2)m-CONR7COR13, -(CH2)n-(Z)g-CONR7COR13, -Het-(CH2)m-(Z)g-CONR7COR13, -(CH2)n-NR10-(CH2)m(CHOR8)n-CONR7COR13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-CONR7COR13, -(CH2)n-(CHOR8)m-CONR7COR13, -Het-(CH2)m-(CHOR8)m-CONR7COR13, -(CH2)n-(CHOR8)m-(Z)g-CONR7COR13, -Het-(CH2)n-(CHOR8)m-CONR7COR13, (CH2)n-(Z)g-(CH2)mCONR7COR13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR7COR13, -(CH2)n-CONR7CO2R13, -(CH2)n-(Z)g-CONR7CO2R13, -Het-(CH2)m-(Z)g-CONR7CO2R13, -(CH2)n-NR10-(CH2)m(CHOR8)n-CONR7CO2R13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-CONR7CO2R13, -(CH2)n-(CHOR8)m-CONR7CO2R13, -Het-(CH2)m-(CHOR8)m-CONR7CO2R13, -(CH2)n-(CHOR8)m-(Z)g-CONR7CO2R13, -Het-(CH2)n-(CHOR8)m-(Z)g-CONR7CO2R13, -(CH2)n-(Z)g-(CH2)m-CONR7CO2R13, -Het-(CH2)n-(Z)g-(CH2)m-CONR7CO2R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR7CO2R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-CONR7CO2R13, -(CH2)n-NH-C(=NR13)-NR13R13, -Het-(CH2)m-NH-C(=NR13)-NR13R13, (CH2)n-(Z)g-NH-C(=NR13)-NR13R13, -Het-(CH2)m-(Z)g-NH-C(=NR13)-NR13R13, (CH2)n-NR10-(CH2)m(CHOR8)n-NH-C(=NR13)NR13R13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-NH-C(=NR13)-NR13R13, -(CH2)n-(CHOR8)m-NH-C(=NR13)-NR13R13, -Het-(CH2)m-(CHOR8)m-NH-C(=NR13)-NR13R13, -(CH2)n-(CHOR8)m-(Z)g-NH-C(=NR13)-NR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-NH-C(=NR13)-NR13R13, -(CH2)n-(Z)g-(CH2)mNH-C(=NR13)-NR13R13, -Het-(CH2)n-(Z)g-(CH2)mNH-C(=NR13)-NR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-NH-C(=NR13)-NR13R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-NH-C(=NR13)-NR13R13, -(CH2)n-C(=NR13)-NR13R13, Het-(CH2)m-C(=NH)-NR13R13, -(CH2)n-(Z)g-C(=NH)-NR13R13, -Het-(CH2)m-(Z)g-C(=NH)-NR13R13, -(CH2)n-NR10-(CH2)m-(CHOR8)n-C(=NR13)-NR13R13, -Het-(CH2)m-NR10-(CH2)m(CHOR8)n-C(=NR13)-NR13R13, -(CH2)n-(CHOR8)m-C(=NR13)-NR13R13, -Het-(CH2)m-(CHOR8)m-C(=NR13)-NR13R13, -(CH2)n-(CHOR8)m-(Z)g-C(=NR13)-NR13R13, -Het-(CH2)n-(CHOR8)m-(Z)g-C(=NR13)-NR13R13, -(CH2)n-(Z)g-(CH2)m-C(=NH)C(=NR13)-NR13R13, Het-(CH2)n-(Z)g-(CH2)m-C(=NR13)-NR13R13, -(CH2)n-(Z)g-(CHOR8)m-(Z)g-C(=NR13)-NR13R13, -Het-(CH2)n-(Z)g-(CHOR8)m-(Z)g-C(NR13)-NR13R13, -(CH2)n-NR12R12, -O-(CH2)m-NR12R12, -O-(CH2)n-NR12R12, -O-(CH2)m-(Z)g-R12, -(CH2)n-NR11R11, -O-(CH2)m-NR11R11, -(CH2)n-N+(R11)3, -O-(CH2)m-N+(R11)3, -(CH2)n-(Z)g-(CH2)m-NR10R10, -O-(CH2)m-(Z)g-(CH2)m-NR10R10, -(CH2CH2O)m-CH2CH2NR12R12, -O-(CH2CH2O)m-CH2CH2NR12R12, -(CH2)n-(C=O)NR12R12, -O-(CH2)m-(C=O)NR12R12, -O-(CH2)m-(CHOR8)mCH2NR10-(Z)g-R10, -(CH2)n-(CHOR8)mCH2-NR10-(Z)g-R10, -(CH2)nNR10-O(CH2)m(CHOR8)nCH2NR10-(Z)g-R10, -O(CH2)m-NR10-(CH2)m(CHOR8)nCH2NR10-(Z)g-R10, -(Het)-(CH2)m-OR8, -(Het)-(CH2)m-NR7R10, -(Het)-(CH2)m(CHOR8)(CHOR8)n-CH2OR8, -(Het)-(CH2CH2O)m-R8, -(Het)-(CH2CH2O)m-CH2CH2NR7R10, -(Het)-(CH2)m-C(=O)NR7R10, (Het)-(CH2)m-(Z)g-R7, -(Het)-(CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -(Het)-(CH2)m-CO2R7, -(Het)-(CH2)m-NR12R12, -(Het)-(CH2)n-NR12R12, -(Het)-(CH2)m-(Z)gR12, -(Het)-(CH2)mNR11R11, -(Het)-(CH2)mN+(R11)3, -(Het)-(CH2)m-(Z)g-(CH2)m-NR10R10, -(Het)-(CH2CH2O)m-CH2CH2NR12R12, -(Het)-(CH2)m-(C=O)NR12R12, -(Het)-(CH2)m-(CHOR8)mCH2NR10-(Z)g-R10, -(Het)-(CH2)m-NR10-(CH2)m-(CHOR8)nCH2NR10-(Z)g-R10, -(CH2)n(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m(CHOR8)(CHOR8)n-CH2OR8, -(CH2)n-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, -O-(CH2)m-NR10-CH2(CHOR8)(CHOR8)n-CH2OR8, Enlace-(CH2)n-CAP, Enlace-(CH2)(CHOR8)(CHOR8)n-CAP, Enlace-(CH2CH2O)m-CH2-CAP, Enlace-(CH2CH2O)m-CH2CH2-CAP, Enlace-(CH2)-(Z)g-CAP, Enlace-(CH2)n-(Z)g-(CH2)m-CAP, Enlace-(CH2)-NR13-CH2(CHOR8)(CHOR8)n-CAP, Enlace-(CH2)n-(CHOR8)m-CH2-NR13-(Z)g-CAP, Enlace-(CH2)NR13-(CH2)m(CHOR8)nCH2NR13-(Z)g-CAP, Enlace-(CH2)m-(Z)g-(CH2)m-CAP, Enlace-NHC(=O)-NH(CH2)m-CAP, Enlace-(CH2)m-C(=O)NR13-(CH2)m-C(=O)NR10R10, Enlace-(CH2)m-C(=O)NR13-(CH2)m-CAP, EnIace-(CH2)m-C(=O)NR11R11, Enlace-(CH2)m-C(=O)NR12R12, Enlace-(CH2)n-(Z)g-(CH2)m-(Z)g-CAP, Enlace-(Z)g-(CH2)m-Het-(CH2)m-CAP, Enlace-(CH2)n-CR11R11-CAP, Enla
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3146608P | 2008-02-26 | 2008-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070527A1 true AR070527A1 (es) | 2010-04-14 |
Family
ID=40998513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100664A AR070527A1 (es) | 2008-02-26 | 2009-02-26 | Bloqueadores poliaromaticos del canal de sodio |
Country Status (14)
Country | Link |
---|---|
US (3) | US8124607B2 (es) |
EP (1) | EP2257296B1 (es) |
JP (1) | JP5611844B2 (es) |
KR (1) | KR101654549B1 (es) |
CN (1) | CN101951913A (es) |
AR (1) | AR070527A1 (es) |
AU (1) | AU2009246799B2 (es) |
BR (1) | BRPI0907823A2 (es) |
CA (1) | CA2713413C (es) |
ES (1) | ES2485642T3 (es) |
MX (1) | MX344703B (es) |
NZ (1) | NZ586940A (es) |
TW (1) | TWI432198B (es) |
WO (1) | WO2009139948A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
US7064129B2 (en) * | 2003-08-18 | 2006-06-20 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
US7807834B2 (en) * | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
CA2702094C (en) | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
AU2009246799B2 (en) | 2008-02-26 | 2014-02-27 | Parion Sciences, Inc. | Poly aromatic pyrazinoylguanidine sodium channel blockers |
US20100074881A1 (en) * | 2008-07-11 | 2010-03-25 | Parion Sciences, Inc. | Multiple nebulizer systems |
CA2838529C (en) | 2011-06-07 | 2020-03-24 | Parion Sciences, Inc. | Methods of treatment |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
CA2839709C (en) | 2011-06-27 | 2020-01-14 | Parion Sciences, Inc. | A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity |
DK2855435T3 (en) | 2012-05-29 | 2018-07-16 | Parion Sciences Inc | DENDRIMER-LIKE AMINOAMIDES WITH SODIUM CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF DRY EYES AND OTHER MILK DISEASES |
ES2674665T3 (es) * | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
UA120343C2 (uk) * | 2012-12-17 | 2019-11-25 | Періон Сайєнсіз, Інк. | Похідні хлорпіразинкарбоксаміду, які мають активність блокування епітеліальних натрієвих каналів |
WO2014099673A1 (en) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
CN103408503B (zh) * | 2013-08-21 | 2015-03-11 | 中国科学院南海海洋研究所 | 一种生物碱类化合物的制备方法及其在制备抑制钙离子通道药物中的应用 |
US9346753B2 (en) | 2013-08-23 | 2016-05-24 | Parion Sciences, Inc. | Dithiol mucolytic agents |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
WO2015128402A1 (en) * | 2014-02-28 | 2015-09-03 | Rhodia Operations | Process for the preparation of precipitated silicas, precipitated silicas and their uses, in particular for the reinforcement of polymers |
US20150376145A1 (en) | 2014-06-30 | 2015-12-31 | Parion Sciences, Inc. | Stable sodium channel blockers |
BR112017016067A2 (pt) | 2015-01-30 | 2018-04-03 | Parion Sciences Inc | agentes mucolíticos de monotiol |
CA2984424A1 (en) | 2015-04-30 | 2016-11-03 | Parion Sciences, Inc. | Novel prodrugs of dithiol mucolytic agents |
GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
WO2023146892A1 (en) * | 2022-01-26 | 2023-08-03 | Parion Sciences, Inc. | Biphenyl-substituted epithelial sodium channel blocking compounds |
WO2023146896A1 (en) * | 2022-01-26 | 2023-08-03 | Parion Sciences, Inc. | Bicyclic-substituted epithelial sodium channel blocking compounds |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE639386A (es) * | 1962-10-30 | |||
US4140776A (en) * | 1977-09-16 | 1979-02-20 | Merck & Co., Inc. | N-pyrazinecarbonyl-N'-acylguanidines |
JPS6034925B2 (ja) | 1979-07-31 | 1985-08-12 | 帝人株式会社 | 持続性鼻腔用製剤およびその製造法 |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4540564A (en) | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
US4479932A (en) | 1982-05-18 | 1984-10-30 | University Of Florida | Brain-specific drug delivery |
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
JPS6032714A (ja) | 1983-08-01 | 1985-02-19 | Teijin Ltd | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
US4604394A (en) * | 1984-10-01 | 1986-08-05 | Merck & Co., Inc. | Antiarrhythmic compositions and method |
US4894376A (en) * | 1988-02-26 | 1990-01-16 | Trustees Of The University Of Pennsylvania | Methods of treating diseases characterized by hyperexcitability of neurons |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5182299A (en) | 1990-03-19 | 1993-01-26 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5492112A (en) | 1991-05-20 | 1996-02-20 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
US5292498A (en) | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
EP0940154B1 (en) | 1991-07-02 | 2007-04-18 | Nektar Therapeutics | Device for delivering aerosolized medicaments |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
CA2147260C (en) | 1992-10-19 | 1999-04-13 | Mark Bernard Mecikalski | Dry powder inhaler |
US5819726A (en) | 1993-01-29 | 1998-10-13 | Aradigm Corporation | Method for the delivery of aerosolized drugs to the lung for the treatment of respiratory disease |
AUPM411494A0 (en) | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5622166A (en) | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5789391A (en) | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
CA2346656A1 (en) | 1998-10-20 | 2000-04-27 | The University Of North Carolina At Chapel Hill | Methods of hydrating mucosal surfaces |
US20040195160A1 (en) * | 1999-07-12 | 2004-10-07 | Marine Desalination Systems, L.L.C. | Hydrate-based reduction of fluid inventories and concentration of aqueous and other water-containing products |
US20040199456A1 (en) * | 2000-08-01 | 2004-10-07 | Andrew Flint | Method and apparatus for explaining credit scores |
US6858614B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
US7064129B2 (en) * | 2003-08-18 | 2006-06-20 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
US20050090505A1 (en) * | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
JP2007502829A (ja) * | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
CA2534568A1 (en) * | 2003-08-18 | 2005-03-24 | Parion Sciences, Inc. | Aliphatic pyrazinoylguanidine sodium channel blockers |
US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
US20090253714A1 (en) | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
US7399766B2 (en) * | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
US8143256B2 (en) * | 2004-08-18 | 2012-03-27 | Parion Sciences, Inc. | Cyclic amide and ester pyrazinoylguanidine sodium channel blockers |
US7956059B2 (en) | 2004-08-18 | 2011-06-07 | Parion Sciences, Inc. | Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers |
US20090324724A1 (en) | 2004-08-18 | 2009-12-31 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
US7807834B2 (en) * | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
GB0526240D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
WO2007146870A1 (en) | 2006-06-09 | 2007-12-21 | Parion Sciences, Inc. | Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
CA2653757A1 (en) | 2006-06-09 | 2007-12-21 | Parion Sciences, Inc. | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity |
WO2007146869A1 (en) * | 2006-06-09 | 2007-12-21 | Parion Sciences, Inc. | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
EA200970258A1 (ru) * | 2006-09-07 | 2009-08-28 | Пэрион Сайенсиз, Инк. | Способ усиления гидратации слизистой оболочки и клиренса слизистой оболочки обработкой блокаторами натриевых каналов и осмолитами |
AR062742A1 (es) * | 2006-09-07 | 2008-12-03 | Johnson Michael R | Hidratacion de la mucosa y depuracion de la mucosa aumentadas por tratamiento con bloquadores de canales de sodio y osmolitos |
US20080293740A1 (en) * | 2007-04-03 | 2008-11-27 | Parion Sciences, Inc. | Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders |
US8288391B2 (en) * | 2007-04-03 | 2012-10-16 | Parion Sciences, Inc. | Pyrazinoylguanidine compounds for use as taste modulators |
DE602008005140D1 (de) | 2007-05-07 | 2011-04-07 | Novartis Ag | Organische verbindungen |
CA2702094C (en) | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
AU2009246799B2 (en) | 2008-02-26 | 2014-02-27 | Parion Sciences, Inc. | Poly aromatic pyrazinoylguanidine sodium channel blockers |
CN102015662A (zh) | 2008-05-13 | 2011-04-13 | 诺瓦提斯公司 | 3,5-二氨基-6-氯-吡嗪-2-甲酸衍生物和它们作为上皮钠通道阻断剂用于治疗气道疾病的用途 |
CN102112130A (zh) | 2008-06-10 | 2011-06-29 | 诺瓦提斯公司 | 作为上皮钠通道阻滞剂的吡嗪衍生物 |
US20100074881A1 (en) | 2008-07-11 | 2010-03-25 | Parion Sciences, Inc. | Multiple nebulizer systems |
-
2009
- 2009-02-26 AU AU2009246799A patent/AU2009246799B2/en not_active Ceased
- 2009-02-26 US US12/393,252 patent/US8124607B2/en not_active Expired - Fee Related
- 2009-02-26 KR KR1020107018978A patent/KR101654549B1/ko active IP Right Grant
- 2009-02-26 JP JP2010548865A patent/JP5611844B2/ja not_active Expired - Fee Related
- 2009-02-26 EP EP09747034.8A patent/EP2257296B1/en not_active Not-in-force
- 2009-02-26 ES ES09747034.8T patent/ES2485642T3/es active Active
- 2009-02-26 MX MX2010009099A patent/MX344703B/es active IP Right Grant
- 2009-02-26 NZ NZ586940A patent/NZ586940A/xx not_active IP Right Cessation
- 2009-02-26 TW TW098106213A patent/TWI432198B/zh not_active IP Right Cessation
- 2009-02-26 AR ARP090100664A patent/AR070527A1/es unknown
- 2009-02-26 CA CA2713413A patent/CA2713413C/en not_active Expired - Fee Related
- 2009-02-26 WO PCT/US2009/035286 patent/WO2009139948A1/en active Application Filing
- 2009-02-26 BR BRPI0907823-1A patent/BRPI0907823A2/pt not_active Application Discontinuation
- 2009-02-26 CN CN2009801062182A patent/CN101951913A/zh active Pending
-
2012
- 2012-01-18 US US13/353,018 patent/US8575176B2/en active Active
-
2013
- 2013-10-01 US US14/043,223 patent/US20140031371A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8575176B2 (en) | 2013-11-05 |
US20120116083A1 (en) | 2012-05-10 |
MX344703B (es) | 2017-01-03 |
JP2011513325A (ja) | 2011-04-28 |
US20140031371A1 (en) | 2014-01-30 |
AU2009246799B2 (en) | 2014-02-27 |
MX2010009099A (es) | 2010-12-06 |
CA2713413A1 (en) | 2009-11-19 |
JP5611844B2 (ja) | 2014-10-22 |
NZ586940A (en) | 2012-08-31 |
EP2257296B1 (en) | 2014-05-07 |
BRPI0907823A2 (pt) | 2015-07-21 |
CN101951913A (zh) | 2011-01-19 |
US8124607B2 (en) | 2012-02-28 |
KR101654549B1 (ko) | 2016-09-07 |
TWI432198B (zh) | 2014-04-01 |
EP2257296A4 (en) | 2011-04-20 |
WO2009139948A1 (en) | 2009-11-19 |
KR20100119878A (ko) | 2010-11-11 |
US20090214444A1 (en) | 2009-08-27 |
EP2257296A1 (en) | 2010-12-08 |
TW200940059A (en) | 2009-10-01 |
CA2713413C (en) | 2018-11-20 |
AU2009246799A1 (en) | 2009-11-19 |
ES2485642T3 (es) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070527A1 (es) | Bloqueadores poliaromaticos del canal de sodio | |
AR062741A1 (es) | Metodo para aumentar la hidratacion de la mucosa y la evacuacion de l a mucosa mediante tratamiento con bloquadores de los canales del sodio y osmolitos | |
ECSP099091A (es) | Profarmaco de compuesto de cinamida | |
EA200601785A1 (ru) | Соединения и способы лечения дислипидемии | |
NO20092380L (no) | Amino-nikotin- og isonikotinsyrederivater anvendelige som DHODH-inhibitorer | |
TW200730514A (en) | Morpholine type cinnamide compound | |
NO20054135L (no) | Kipolinon/benzoksazin derivater og anvendelser derav | |
EA200801607A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
CY1112859T1 (el) | Αλας καλιου αναστολεα της ιντεγκρασης του ηiv | |
CY1113715T1 (el) | Αναλογα πυριδονης και πυριδαζονης ως ρυθμιστες toy gpr119 | |
PE20121311A1 (es) | Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos | |
EA200702002A1 (ru) | Замещённые производные пиразолилоксифенила, применяемые в качестве гербицидов | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
ECSP088677A (es) | Piperazinas y piperidinas como potenciadores 157 del mglur5 | |
NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
EA200600225A1 (ru) | Производные пиперазина для лечения вич инфекций | |
PE20090189A1 (es) | Derivados de aza-piridopirimidinona como agonistas de hm74a | |
AR057433A1 (es) | Compuestos quimicos derivados de piridopirimidina, un metodo para su preparacion y composicion farmaceutica | |
CY1114354T1 (el) | Νεα παραγωγα βενζαμιδιου ως ανταγωνιστες βραδυκινινης | |
MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
CY1106716T1 (el) | 4-υποκαθισταμενα παραγωγα πιπεριδινης | |
ECSP10010425A (es) | Pirrolopirimidincarboxamidas | |
HRP20041202A2 (en) | Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof | |
MY136824A (en) | Substituted benzoxazinones and uses thereof | |
CY1113535T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |